{"id":"W2033816200","doi":"10.1016/s1470-2045(14)71135-0","title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":544,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; Université Laval; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Carboplatin; Tolerability; Internal medicine; Regimen; Ovarian cancer; Chemotherapy; Oncology; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Phases of clinical research; Urology; Cancer; Randomized controlled trial; Cisplatin; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001281428,0.0002325234,0.001104364,0.00005660988,0.0001607165,0.00001615391,0.0001585788,0.0001528323,0.0002255932],"category_scores_gemma":[0.0001444351,0.0001417746,0.0001402039,0.000159517,0.0002564161,0.00003593995,0.00001072852,0.0003257056,0.00001148917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003122663,"about_ca_system_score_gemma":0.0004016482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003397959,"about_ca_topic_score_gemma":0.0000995833,"domain_scores_codex":[0.9982433,0.0003865693,0.0003851531,0.0003359944,0.000205071,0.0004438811],"domain_scores_gemma":[0.9977868,0.001113923,0.0003330601,0.0004545813,0.0001961198,0.0001155066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9269211,0.0005837316,0.00002367061,0.00004037392,0.000359983,0.000006240074,0.001097791,0.00001461533,0.003906357,0.002195641,0.0192545,0.04559604],"study_design_scores_gemma":[0.7619015,0.01912303,0.00007515105,0.00009453724,0.0001849673,0.00004039328,0.00006304402,0.001549748,0.007345175,0.000861339,0.2085955,0.0001656442],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8005265,0.0002836796,0.0281658,0.1340322,0.003014333,0.01416003,0.000240022,0.0003874321,0.01918997],"genre_scores_gemma":[0.9655396,0.0003215695,0.003448804,0.01981188,0.006624247,0.003494547,0.0001260518,0.00007640399,0.0005569159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.189341,"threshold_uncertainty_score":0.5781399,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05582660886094198,"score_gpt":0.3904644590514653,"score_spread":0.3346378501905233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}